Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Genoprotective Effects of Essential Oil Compounds Against Oxidative and Methylated DNA Damage in Human Colon Cancer Cells.

Thapa D, Richardson AJ, Zweifel B, Wallace RJ, Gratz SW.

J Food Sci. 2019 Jun 17. doi: 10.1111/1750-3841.14665. [Epub ahead of print]

PMID:
31206673
2.

In Reply to Dr. Schrimpf.

Zweifel B, Procter E, Techel F, Strapazzon G, Boutellier R.

Wilderness Environ Med. 2016 Sep;27(3):441. doi: 10.1016/j.wem.2016.06.050. No abstract available.

PMID:
27591710
3.

Burial duration, depth and air pocket explain avalanche survival patterns in Austria and Switzerland.

Procter E, Strapazzon G, Dal Cappello T, Zweifel B, Würtele A, Renner A, Falk M, Brugger H.

Resuscitation. 2016 Aug;105:173-6. doi: 10.1016/j.resuscitation.2016.06.001. Epub 2016 Jun 14.

PMID:
27312137
4.

Risk of Avalanche Involvement in Winter Backcountry Recreation: The Advantage of Small Groups.

Zweifel B, Procter E, Techel F, Strapazzon G, Boutellier R.

Wilderness Environ Med. 2016 Jun;27(2):203-10. doi: 10.1016/j.wem.2015.12.001. Epub 2016 Feb 9.

PMID:
26873158
5.

Essential oils have different effects on human pathogenic and commensal bacteria in mixed faecal fermentations compared with pure cultures.

Thapa D, Louis P, Losa R, Zweifel B, Wallace RJ.

Microbiology. 2015 Feb;161(Pt 2):441-9. doi: 10.1099/mic.0.000009. Epub 2014 Dec 12.

PMID:
25500493
6.

PAS kinase drives lipogenesis through SREBP-1 maturation.

Wu X, Romero D, Swiatek WI, Dorweiler I, Kikani CK, Sabic H, Zweifel BS, McKearn J, Blitzer JT, Nickols GA, Rutter J.

Cell Rep. 2014 Jul 10;8(1):242-55. doi: 10.1016/j.celrep.2014.06.006. Epub 2014 Jul 4.

7.

The effectiveness of avalanche airbags.

Haegeli P, Falk M, Procter E, Zweifel B, Jarry F, Logan S, Kronholm K, Biskupič M, Brugger H.

Resuscitation. 2014 Sep;85(9):1197-203. doi: 10.1016/j.resuscitation.2014.05.025. Epub 2014 Jun 6.

PMID:
24909367
8.

Leukotrienes, but not angiotensin II, are involved in the renal effects elicited by the prolonged cyclooxygenase-2 inhibition when sodium intake is low.

Salazar F, Salazar FJ, Saez F, Reverte V, Zweifel B, Dufield D, Radabaugh M, Graneto M, Llinas MT, Masferrer JL.

J Cardiovasc Pharmacol. 2013 Apr;61(4):329-36. doi: 10.1097/FJC.0b013e31828399ae.

PMID:
23288201
9.

Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.

Arhancet GB, Walker DP, Metz S, Fobian YM, Heasley SE, Carter JS, Springer JR, Jones DE, Hayes MJ, Shaffer AF, Jerome GM, Baratta MT, Zweifel B, Moore WM, Masferrer JL, Vazquez ML.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):1114-9. doi: 10.1016/j.bmcl.2012.11.109. Epub 2012 Dec 6.

PMID:
23260349
10.

Sensitivity of pathogenic and commensal bacteria from the human colon to essential oils.

Thapa D, Losa R, Zweifel B, Wallace RJ.

Microbiology. 2012 Nov;158(Pt 11):2870-7. doi: 10.1099/mic.0.061127-0. Epub 2012 Aug 9.

PMID:
22878397
11.

A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.

Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, Hall T, Johnston A, Murphy M, Nemirovskiy O, Ogawa S, Pegg L, Pelc M, Prinsen M, Schnute M, Wendling J, Wene S, Weinberg R, Wittwer A, Zweifel B, Masferrer J.

J Pharmacol Exp Ther. 2010 Jul;334(1):310-7. doi: 10.1124/jpet.110.165845. Epub 2010 Apr 14.

PMID:
20392816
12.

Pharmacology of PF-4191834, a novel, selective non-redox 5-lipoxygenase inhibitor effective in inflammation and pain.

Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L, Pufahl RA, Graneto M.

J Pharmacol Exp Ther. 2010 Jul;334(1):294-301. doi: 10.1124/jpet.110.166967. Epub 2010 Apr 8.

PMID:
20378715
13.

Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity.

Rajagopalan LE, Davies MS, Kahn LE, Kornmeier CM, Shimada H, Steiner TA, Zweifel BS, Wendling JM, Payne MA, Loeffler RF, Case BL, Norton MB, Parikh MD, Nemirovskiy OV, Mourey RJ, Masferrer JL, Misko TP, Kolodziej SA.

J Pharmacol Exp Ther. 2010 Jun;333(3):707-16. doi: 10.1124/jpet.110.166033. Epub 2010 Mar 12.

PMID:
20228155
14.

Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.

Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL.

Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11.

PMID:
20067770
15.

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.

Cortes-Burgos LA, Zweifel BS, Settle SL, Pufahl RA, Anderson GD, Hardy MM, Weir DE, Hu G, Happa FA, Stewart Z, Muthian S, Graneto MJ, Masferrer JL.

Eur J Pharmacol. 2009 Sep 1;617(1-3):59-67. doi: 10.1016/j.ejphar.2009.06.058. Epub 2009 Jul 4.

PMID:
19580807
16.

A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.

Zweifel BS, Hardy MM, Anderson GD, Dufield DR, Pufahl RA, Masferrer JL.

Eur J Pharmacol. 2008 Apr 14;584(1):166-74. doi: 10.1016/j.ejphar.2008.01.021. Epub 2008 Feb 5.

PMID:
18295198
17.

The impact of avalanche rescue devices on survival.

Brugger H, Etter HJ, Zweifel B, Mair P, Hohlrieder M, Ellerton J, Elsensohn F, Boyd J, Sumann G, Falk M.

Resuscitation. 2007 Dec;75(3):476-83. Epub 2007 Aug 6.

PMID:
17689170
18.

Enzymologic and pharmacologic profile of loxoprofen sodium and its metabolites.

Noguchi M, Kimoto A, Gierse JK, Walker MC, Zweifel BS, Nozaki K, Sasamata M.

Biol Pharm Bull. 2005 Nov;28(11):2075-9.

19.

COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.

Narko K, Zweifel B, Trifan O, Ristimäki A, Lane TF, Hla T.

Prostaglandins Other Lipid Mediat. 2005 May;76(1-4):86-94.

PMID:
15967164
20.

Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.

Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.

J Pharmacol Exp Ther. 2005 Mar;312(3):1206-12. Epub 2004 Oct 19.

PMID:
15494548
21.

Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature.

Davis TW, O'Neal JM, Pagel MD, Zweifel BS, Mehta PP, Heuvelman DM, Masferrer JL.

Cancer Res. 2004 Jan 1;64(1):279-85.

22.

Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting.

Davis TW, Zweifel BS, O'Neal JM, Heuvelman DM, Abegg AL, Hendrich TO, Masferrer JL.

J Pharmacol Exp Ther. 2004 Mar;308(3):929-34. Epub 2004 Jan 7.

PMID:
14711936
23.

The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.

Lanza-Jacoby S, Miller S, Flynn J, Gallatig K, Daskalakis C, Masferrer JL, Zweifel BS, Sembhi H, Russo IH.

Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1486-91.

24.

Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.

Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM.

Mol Carcinog. 2003 Oct;38(2):49-58.

PMID:
14502644
25.

Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.

Wilgus TA, Koki AT, Zweifel BS, Rubal PA, Oberyszyn TM.

Mol Carcinog. 2003 Sep;38(1):33-9.

PMID:
12949841
26.

Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.

Cancer Res. 2002 Nov 15;62(22):6706-11.

27.

Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.

Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, Davis TW, Masferrer JL.

Cancer Res. 2002 Oct 15;62(20):5778-84.

28.

Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL.

Cancer Res. 2002 Feb 1;62(3):625-31.

29.

Selective inhibition of Delta-6 desaturase impedes intestinal tumorigenesis.

Hansen-Petrik MB, McEntee MF, Johnson BT, Obukowicz MG, Masferrer J, Zweifel B, Chiu CH, Whelan J.

Cancer Lett. 2002 Jan 25;175(2):157-63.

PMID:
11741743
30.

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K.

Cancer Res. 2000 Mar 1;60(5):1306-11.

31.

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.

Talley JJ, Brown DL, Carter JS, Graneto MJ, Koboldt CM, Masferrer JL, Perkins WE, Rogers RS, Shaffer AF, Zhang YY, Zweifel BS, Seibert K.

J Med Chem. 2000 Mar 9;43(5):775-7. No abstract available.

PMID:
10715145
32.

Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation.

Michaluart P, Masferrer JL, Carothers AM, Subbaramaiah K, Zweifel BS, Koboldt C, Mestre JR, Grunberger D, Sacks PG, Tanabe T, Dannenberg AJ.

Cancer Res. 1999 May 15;59(10):2347-52.

33.

Synthesis and activity of sulfonamide-substituted 4,5-diaryl thiazoles as selective cyclooxygenase-2 inhibitors.

Carter JS, Kramer S, Talley JJ, Penning T, Collins P, Graneto MJ, Seibert K, Koboldt CM, Masferrer J, Zweifel B.

Bioorg Med Chem Lett. 1999 Apr 19;9(8):1171-4.

PMID:
10328307
34.

Pharmacological analysis of cyclooxygenase-1 in inflammation.

Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8.

35.

Regulation of prostaglandin biosynthesis in vivo by glutathione.

Margalit A, Hauser SD, Zweifel BS, Anderson MA, Isakson PC.

Am J Physiol. 1998 Feb;274(2):R294-302. doi: 10.1152/ajpregu.1998.274.2.R294.

PMID:
9486284
36.

Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents.

Li JJ, Norton MB, Reinhard EJ, Anderson GD, Gregory SA, Isakson PC, Koboldt CM, Masferrer JL, Perkins WE, Seibert K, Zhang Y, Zweifel BS, Reitz DB.

J Med Chem. 1996 Apr 26;39(9):1846-56.

PMID:
8627608
37.

The Role of Cyclooxygenase-2 in Inflammation.

Masferrer JL, Zweifel BS, Colburn SM, Ornberg RL, Salvemini D, Isakson P, Seibert K.

Am J Ther. 1995 Sep;2(9):607-610.

PMID:
11854834
38.

Poly(ADP-ribose) quantification at the femtomole level in mammalian cells.

Malanga M, Bachmann S, Panzeter PL, Zweifel B, Althaus FR.

Anal Biochem. 1995 Jul 1;228(2):245-51.

PMID:
8572302
39.

Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors.

Salvemini D, Manning PT, Zweifel BS, Seibert K, Connor J, Currie MG, Needleman P, Masferrer JL.

J Clin Invest. 1995 Jul;96(1):301-8.

40.

Interactions of poly(ADP-ribose) with nuclear proteins.

Althaus FR, Bachmann S, Höfferer L, Kleczkowska HE, Malanga M, Panzeter PL, Realini C, Zweifel B.

Biochimie. 1995;77(6):423-32.

PMID:
7578424
41.

In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages.

Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P, Gilbert RS, Herschman HR.

J Pharmacol Exp Ther. 1994 Sep;270(3):1340-4.

PMID:
7932188
42.

Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K.

Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3228-32.

43.

Targeting of histone tails by poly(ADP-ribose).

Panzeter PL, Zweifel B, Malanga M, Waser SH, Richard M, Althaus FR.

J Biol Chem. 1993 Aug 25;268(24):17662-4.

44.

Synthesis of poly(ADP-ribose)-agarose beads: an affinity resin for studying (ADP-ribose)n-protein interactions.

Panzeter PL, Zweifel B, Althaus FR.

Anal Biochem. 1992 Nov 15;207(1):157-62.

PMID:
1489089
45.

Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme.

Masferrer JL, Seibert K, Zweifel B, Needleman P.

Proc Natl Acad Sci U S A. 1992 May 1;89(9):3917-21.

46.

The alpha-glycosidic bonds of poly(ADP-ribose) are acid-labile.

Panzeter PL, Zweifel B, Althaus FR.

Biochem Biophys Res Commun. 1992 Apr 15;184(1):544-8.

PMID:
1567456
47.
48.

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice.

Masferrer JL, Zweifel BS, Seibert K, Needleman P.

J Clin Invest. 1990 Oct;86(4):1375-9.

49.

Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits.

Daugherty A, Zweifel BS, Schonfeld G.

Br J Pharmacol. 1989 Oct;98(2):612-8.

50.

Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe heritable hyperlipidemic rabbits.

Daugherty A, Zweifel BS, Sobel BE, Schonfeld G.

Arteriosclerosis. 1988 Nov-Dec;8(6):768-77.

PMID:
3196220

Supplemental Content

Loading ...
Support Center